NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders. The company’s product candidates have successfully completed 17 pre-clinical, Phase I, Phase I/II, and Phase II clinical studies, and is entering clinical trials for the treatment of patients with severe Parkinson’s disease, migraine, post operative cognitive dysfunction (POCD), and inclusion-body myositis (IBM). Further studies are contemplated for ALS, Huntington’ Diseases, Alzheimer’s disease, and Encephalitis. Nearly $100 million has been invested on developing NE3107. The company’s focus is on diseases with tremendous unmet medical needs in order to expedite FDA approvals and commercialization, minimize capital requirement and optimize shareholder value.
The NeurMedix, Inc. IPO is a Tier 2 Reg A+ offering.
Until the SEC Qualifies the Offering Statement
No money or other consideration is being solicited, and if sent in response, will not be accepted;
No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
A person’s indication of interest involves no obligation or commitment of any kind;
Under corprate communication you will find Included a complete copy of the Preliminary Offering Circular.
For more information, please fill out the form below: